News

Novo Integrated Sciences’ Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program

BELLEVUE, Wash.--(BUSINESS WIRE)--$NVOS #AAPI--As previously reported, the Board of Directors (the “Board”) of Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the…

2 years ago

e4life, the New Frontier in the Battle Against Viruses Has Arrived in the United Kingdom Thanks to a Patented Italian Device Which Uses Electromagnetic Waves to Inactivate Them

BIRMINGHAM, United Kingdom--(BUSINESS WIRE)--As part of the MedTech Innovation Expo, the leading trade show in the medical device design and…

2 years ago

nference to Present AI-Driven Research at 2024 ASCO Annual Meeting

AI workflow enhances precision of progression-free survival estimates in metastatic breast cancer, enabling more effective and personalized treatmentsCAMBRIDGE, Mass.--(BUSINESS WIRE)--nference,…

2 years ago

 Masimo Announces Nomination of Independent Candidate to the Board of Directors

 Experienced Medical Device Executive Christopher Chavez to Stand for Election at 2024 Annual Meeting Company Extends Third Settlement Offer to…

2 years ago

Unite Us CPTO, Raffalle Breaks, Recognized as a Top 25 Healthcare Software Executive of 2024 for Social Care Contributions

The Healthcare Technology Report has released its annual list of top executives, recognizing the industry's leaders for their innovative contributions…

2 years ago

Sound Physicians Closes Liquidity Enhancing Transaction

Strengthening its financial position with an infusion of new capital that will bolster its operations and practices, coast to coastNEW…

2 years ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

NEWARK, CA / ACCESSWIRE / May 31, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh…

2 years ago

FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest

TORONTO, ON / ACCESSWIRE / May 31, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to…

2 years ago

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with…

2 years ago

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced…

2 years ago